Abstract
Type-2 diabetes is strongly linked to visceral obesity and elevated levels of circulating free fatty acids. For years this correlation of obesity to diabetes has intrigued the minds of researchers and research in this direction has led to a possible solution to this question. Human Genome project has identified nearly 150 orphan GPCRs. The reverse pharmacology approaches have identified free fatty acids as ligands for the GPR40 family of orphan receptors. This review mainly emphasizes on the role of GPR40 carboxylic acid receptor family in the development of diabetes alongwith detailed coverage of each receptor of the family. GPR40 family has provided an insight into regulation of carbohydrate and lipid metabolism in vertebrates and has further provided targets for the development of therapeutic agents useful for treating or preventing disorders such as Type-2 diabetes. This review also suggests where further research and development could be beneficial.
Keywords: G- protein coupled receptor, tyrosine kinase receptor, orphan GPCR, GPR40 carboxylic acid family, free fatty acids, type 2 diabetes, glucose stimulated insulin secretion, oligomerisation
Current Drug Targets
Title: GPR40 Carboxylic Acid Receptor Family and Diabetes: A New Drug Target
Volume: 9 Issue: 10
Author(s): V. N. Telvekar and H. S. Kundaikar
Affiliation:
Keywords: G- protein coupled receptor, tyrosine kinase receptor, orphan GPCR, GPR40 carboxylic acid family, free fatty acids, type 2 diabetes, glucose stimulated insulin secretion, oligomerisation
Abstract: Type-2 diabetes is strongly linked to visceral obesity and elevated levels of circulating free fatty acids. For years this correlation of obesity to diabetes has intrigued the minds of researchers and research in this direction has led to a possible solution to this question. Human Genome project has identified nearly 150 orphan GPCRs. The reverse pharmacology approaches have identified free fatty acids as ligands for the GPR40 family of orphan receptors. This review mainly emphasizes on the role of GPR40 carboxylic acid receptor family in the development of diabetes alongwith detailed coverage of each receptor of the family. GPR40 family has provided an insight into regulation of carbohydrate and lipid metabolism in vertebrates and has further provided targets for the development of therapeutic agents useful for treating or preventing disorders such as Type-2 diabetes. This review also suggests where further research and development could be beneficial.
Export Options
About this article
Cite this article as:
Telvekar N. V. and Kundaikar S. H., GPR40 Carboxylic Acid Receptor Family and Diabetes: A New Drug Target, Current Drug Targets 2008; 9 (10) . https://dx.doi.org/10.2174/138945008785909301
DOI https://dx.doi.org/10.2174/138945008785909301 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cognitive Function and Quality of Life in Mild Thyroid Hormone Deficiency
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients
Cardiovascular & Hematological Disorders-Drug Targets Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review
Current Drug Therapy Goto-kakizaki Rats: Its Suitability as Non-obese Diabetic Animal Model for Spontaneous Type 2 Diabetes Mellitus
Current Diabetes Reviews C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets The Medical and Medico-legal Complications of Bulimia Nervosa : Treatments and Complications
Current Women`s Health Reviews TGFb and its Smad Connection to Cancer
Current Genomics MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Comparative Proteomics of Liver of the Diabetic Obese db/db and Non-Obese or Diabetic Mice
Current Proteomics Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets Infant Breast-Feeding and Suppression of Biomarkers of Future Cardiovascular Disease
Current Nutrition & Food Science Future of Cardiac Pacemaker – an Update of Biological Pacemaker Patents
Recent Patents on Biomedical Engineering (Discontinued) Bilirubin Chemistry and Metabolism; Harmful and Protective Aspects
Current Pharmaceutical Design